All‐oral direct‐acting antiviral therapy in HCV‐advanced liver disease is effective in real‐world practice: observations through HCV‐TARGET database

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Alimentary Pharmacology and Therapeutics

• Publication date

  2017-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/apt.13823PMID 27790729
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.

  2016cited by this paper
• Review article: safety and tolerability of direct‐acting anti‐viral agents in the new era of hepatitis C therapy

  2016cited by this paper
• Effectiveness and tolerability of simeprevir and sofosbuvir in nontransplant and post‐liver transplant patients with hepatitis C genotype 1

  2016cited by this paper
• Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis.

  2016cited by this paper
• Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.

  2015cited by this paper
• Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation

  2015cited by this paper
• Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis

  2015cited by this paper
• Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C–Infected Patients With Compensated and Decompensated Cirrhosis

  2015cited by this paper
• Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.

  2015cited by this paper
• Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.

  2015cited by this paper
• O002 : Treatment of decompensated HCV cirrhosis in patients with diverse genotypes: 12 weeks sofosbuvir and NS5A inhibitors with/without ribavirin is effective in HCV genotypes 1 and 3

  2015cited by this paper
• O008 : Efficacy and safety of grazoprevir and elbasvir in hepatitis C genotype 1-infected patients with child–pugh class B cirrhosis (C-salt part A)

  2015cited by this paper
• Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.

  2014cited by this paper
• Sofosbuvir and ribavirin in HCV genotypes 2 and 3.

  2014cited by this paper
• Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.

  2014cited by this paper
• Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.

  2013cited by this paper
• Sofosbuvir for previously untreated chronic hepatitis C infection.

  2013cited by this paper
• svr results of a once-daily regimen of simeprevir (tmc435) plus sofosbuvir (gs-7977) with or without ribavirin in cirrhotic and non-cirrhotic Hcv genotype 1 treatment-naïve and prior null responder patients: The Cosmos study : lb-3

  2013cited by this paper
• Management of the transplant recipient with chronic hepatitis C.

  2013cited by this paper
• Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

  2012cited by this paper
• Epidemiology of viral hepatitis and hepatocellular carcinoma.

  2012cited by this paper
• The Increasing Burden of Mortality From Viral Hepatitis in the United States Between 1999 and 2007

  2012cited by this paper
• A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C.

  2011cited by this paper
• Treating hepatitis C in patients with cirrhosis: the effort is worth it.

  2010cited by this paper
• Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression

  2010cited by this paper
• Long‐term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B

  2010cited by this paper
• Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression.

  2010cited by this paper
• Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support

  2009cited by this paper
• Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin.

  2008cited by this paper
• Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT‐C trial

  2006cited by this paper
• PACKAGE INSERT

  2004cited by this paper
• Course and outcome of hepatitis C

  2002cited by this paper
• Estimating progression to cirrhosis in chronic hepatitis C virus infection

  2001cited by this paper

• Resistance‐Associated Substitution Testing Trends and Impact on HCV Treatment Outcomes in Canada: A CanHepC‐CANUHC Analysis

  2025cites this paper
• Recompensation in decompensated cirrhosis.

  2025cites this paper
• Controversies of Direct-Acting Antivirals in Hepatocellular Carcinoma.

  2023cites this paper
• Evaluation of patients treated with direct-acting anti-viral therapy for chronic hepatitis C and their risk of hepatocellular carcinoma in Hong Kong

  2023cites this paper
• Global treatment rate and barriers to direct‐acting antiviral therapy: A systematic review and meta‐analysis of 146 studies and 1 760 352 hepatitis C virus patients

  2023cites this paper
• Assessment of hepatic fibrosis, portal hemodynamic changes, and disease severity in patients with HCV-related liver cirrhosis after sustained virologic response to direct-acting antiviral drugs (DAAs)

  2023cites this paper
• Managing HBV and HCV Infection Pre- and Post-liver Transplant.

  2023cites this paper
• Assessment of Changes in Liver Fibrosis and Stiffness, Lipid Profile and Insulin Resistance in Patients with Chronic Hepatitis C Viral Infection Who Received Direct Acting Antiviral Therapy

  2022cites this paper
• Efficacy and Safety of Sofosbuvir and Ribavirin in an Italian Cohort of HCV Genotype 2 Elderly Cirrhotic Patients

  2022influential citation
• Development of hepatocellular carcinoma in patients with chronic hepatitis C who had sustained viral response following direct-acting antiviral therapy

  2022cites this paper
• Effect of Direct-Acting Antiviral Agents on Gastroesophageal Varices in Patients with Hepatitis C Virus-Related Cirrhosis

  2022cites this paper
• Uptake of interferon‐free DAA therapy among HCV‐infected decompensated cirrhosis patients and evidence for decreased mortality

  2021cites this paper
• Tertiary Prevention of HCC in Chronic Hepatitis B or C Infected Patients

  2021cites this paper
• Real‐world effectiveness and safety of direct‐acting antivirals in patients with cirrhosis and history of hepatic decompensation: Epi‐Ter2 Study

  2021cites this paper
• Role of Serum Vitamin D, Interleukin 13, and microRNA-135a in Hepatocellular Carcinoma and Treatment Failure in Egyptian HCV-Infected Patients Receiving Direct Antiviral Agents

  2021cites this paper
• Safety and efficacy of sofosbuvir/ledipasvir and sofosbuvir/daclatasvir in the treatment of hepatitis C in patients with decompensated cirrhosis

  2021cites this paper
• Real‐world experiences with direct‐acting antiviral agents for chronic hepatitis C treatment

  2020cites this paper
• Pangenotypic direct acting antivirals for the treatment of chronic hepatitis C virus infection: A systematic literature review and meta-analysis

  2020cites this paper
• Effectiveness of Glecaprevir/Pibrentasvir for Hepatitis C: Real-World Experience and Clinical Features of Retreatment Cases

  2020cites this paper
• Real-Life Effectiveness and Safety of Sofosbuvir-Based Therapy in Genotype 2 Chronic Hepatitis C Patients in South Korea, with Emphasis on the Ribavirin Dose

  2020cites this paper
• Outcomes of Hepatitis C Virus Treatment in the New York City Jail Population: Successes and Challenges Facing Scale up of Care

  2020cites this paper
• The hepatitis C virus care cascade in the New York City jail system during the direct acting antiviral treatment era, 2014–2017

  2020cites this paper
• Liver-related effects of chronic hepatitis C antiviral treatment

  2020cites this paper
• Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data.

  2020cites this paper
• Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension.

  2020cites this paper
• Serum MicroRNA Signatures in Recovery From Acute and Chronic Liver Injury and Selection for Liver Transplantation

  2020cites this paper
• Time‐dependent improvement of liver inflammation, fibrosis and metabolic liver function after successful direct‐acting antiviral therapy of chronic hepatitis C

  2020cites this paper
• DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort.

  2020cites this paper
• Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV‐TARGET Analysis

  2019cites this paper
• AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review.

  2019cites this paper
• Hepatitis C virus therapy in advanced liver disease: Outcomes and challenges

  2019cites this paper
• Evolution of HCV patient characteristics and DAA regimens in the German Hepatitis C Registry (DHC-R) in 2014 and 2015

  2019cites this paper
• Direct-Acting Antivirals for Hepatitis C: Predictors of Early Discontinuation in the Real World.

  2019cites this paper
• B.A.R.C.O.S. (Brazilian Argentine Hepatitis C Collaborative Observational Study): Effectiveness and clinical outcomes of HCV treatment with daclatasvir and sofosbuvir with or without ribavirin

  2019cites this paper
• Initial uptake, time to treatment, and real-world effectiveness of all-oral direct-acting antivirals for hepatitis C virus infection in the United States: A retrospective cohort analysis

  2019cites this paper
• IDDF2019-ABS-0211 Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5 or 6 infection: an integrated analysis of phase 2 and 3 studies

  2019cites this paper
• Oral direct-acting antivirals and the incidence or recurrence of hepatocellular carcinoma: a systematic review and meta-analysis

  2018cites this paper
• Hepatitis C eradication with DAA and risk of liver cancer recurrence: The debate unrests

  2018cites this paper
• Sustained Virologic Response and Costs Associated with Direct-Acting Antivirals for Chronic Hepatitis C Infection in Oklahoma Medicaid

  2018cites this paper
• The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver

  2018cites this paper
• Hepatitis C antibody reactivity among high-risk rural women: opportunities for services and treatment in the criminal justice system.

  2018cites this paper
• Expanding Capacity to Treat Hepatitis C: Overcoming Barriers and New Innovations

  2018cites this paper
• Rates of sustained virological response 12 weeks after the scheduled end of direct‐acting antiviral (DAA)‐based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?

  2018cites this paper
• Impact of diabetes mellitus and hepatitis B virus coinfection on patients with chronic hepatitis C: A territory‐wide cohort study

  2018cites this paper
• Diagnosis and monitoring of HCV infection using the cobas® HCV test for use on the cobas® 6800/8800 systems.

  2018cites this paper
• Integrated Care for the Use of Direct-acting Antivirals in Patients With Chronic Hepatitis C and Substance Use Disorder

  2018cites this paper
• Sofosbuvir and daclatasvir therapy in patients with hepatitis C‐related advanced decompensated liver disease (MELD ≥ 15)

  2018cites this paper
• The effectiveness and safety of ledipasvir plus sofosbuvir in adolescents with chronic hepatitis C virus genotype 4 infection: a real‐world experience

  2018cites this paper
• Overview of Direct-Acting Antiviral Drugs and Drug Resistance of Hepatitis C Virus.

  2018cites this paper
• Sofosbuvir‐based treatment regimens: real life results of 14 409 chronic HCV genotype 4 patients in Egypt

  2017cites this paper
• Public-Private Partnership: Targeting Real-World Data for Hepatitis C Direct-Acting Antivirals.

  2017cites this paper
• Effectiveness of 8‐ or 12‐weeks of ledipasvir and sofosbuvir in real‐world treatment‐naïve, genotype 1 hepatitis C infected patients

  2017cites this paper
• Safety and efficacy of sofosbuvir‐based direct‐acting antiviral regimens for hepatitis C virus genotypes 1‐4 and 6 in Myanmar: Real‐world experience

  2017cites this paper
• Systematic review: interferon‐free regimens for patients with HCV‐related Child C cirrhosis

  2017cites this paper
• Planning and prioritizing direct-acting antivirals treatment for HCV patients in countries with limited resources: Lessons from the Egyptian experience.

  2017cites this paper
• Hepatitis C Treatment Regimens Are Cost-Effective: But Compared With What?

  2017cites this paper
• Immune protection against reinfection with nonprimate hepacivirus

  2017cites this paper
• Racial Disparity in Gastrointestinal Cancer Risk.

  2017cites this paper
• Efectividad de la terapia combinada con Simeprevir y Sofosbuvir en pacientes con hepatitis crónica por VHC

  2017cites this paper